International Biotechnol... Share Discussion Threads

[philo124] 23/5/2014 15:37

On the mend.

[rcturner2] 12/5/2014 07:33

Most of the column was about Biotech and he prefers this over BIOG based on the discount. He gave quite a good analysis as to why the long term prospects are very good for the Biotech industry.

[philo124] 12/5/2014 07:30

Good! I am stuffed out with them. Thanks.

[rcturner2] 12/5/2014 07:26

John Barron bigged this one up in the IC on Friday in his IT column.

[philo124] 22/4/2014 15:04

Nice move. Half yearly report out this a.m. .

[barnold] 22/4/2014 07:25

Tipped in this weeks moneyweek along with BIOG. Oversold.

[rogerrail] 15/4/2014 15:04

Did not transpire, NBI finshed flat!

[rogerrail] 14/4/2014 15:15

Discount to NAV now 26% , NBI rising to +2%, if you think it will continue then need to buy before 4:30 , tomorrow morining will be too late to catch the rise!

[davebowler] 14/4/2014 11:03

Date NAV Pence
Friday 11 Apr Ex Income 318.28

[maurillac] 14/4/2014 07:31

good to see that the discount protects you here ;)
m

[trader2] 11/4/2014 05:30

^NBI now off 18.5% from recent high - so not yet in bear market territory (classical definition of a bear market).

[rcturner2] 10/4/2014 08:45

davebowler - good find. All valid points in the article, but hence why I like the IT route in, as the discount protects you.

[davebowler] 10/4/2014 08:38

hxxp://www.fundweb.co.uk/2008988.article?cmpid=fwam_216034

[rogerrail] 09/4/2014 15:18

current prices of top 9 holdings & NBI:


NBI
2,404.92 +46.34
1.96%
VRTX 66.69 +1.34
2.05%
REGN 299.85 +13.41
4.68%
BIIB 291.12 +5.20
1.82%
CELG 143.26 +5.04
3.65%
MYL 47.81 +0.17
0.35%
AMGN 118.46 +0.48
0.41%
ALXN 151.10 +3.44
2.33%
ILMN 142.76 +0.94
0.66%
GILD 70.43 +0.42
0.60%

[rogerrail] 09/4/2014 15:17

NBI index currently up 2% , CELG and REGN up 4%, even GILD is up.
Bodes well for a widening of the discount to NAV tomorrow LOL!

[davebowler] 09/4/2014 13:08

Westhouse's data do reveal further weakness in the NAV since the last actual NAV
release by IBT. This has been led by the fund's positions in Gilead Sciences (GILD US)
and Biogen Idec (BIIB US). Yet this softness in the NAV is now arguably more than
reflected in IBT's discount pricing relative to its peers.




It was another rollercoaster day for the biotech stocks yesterday (both funds
and underlying stocks), with key stocks partly recovering from initial falls.
International Biotechnology Trust (IBT.L, discount -24.2%, Buy) is shortly due to
announce its interim results to the end of February and, given the value that
has opened up on this fund, the views of the manager with regard to recent
events and forward expectations will be particularly interesting when we
meet at an analyst meeting planned for 22 April.

[tokyo sexwhale] 09/4/2014 11:03

Confirmed it is and looks to have bottomed for now

[rogerrail] 09/4/2014 09:58

Suspect the NAV will be broadly the same as yesterday as NBI index was again flat last night.

[tokyo sexwhale] 09/4/2014 08:37

Expect this to rise sharply today once NAV announced not too late to top up prior

[snowydays] 08/4/2014 12:59

After being 10% down earlier today BIOG has turned around is is back to near the opening price. Let's hope IBT can follow suit.

[rogerrail] 08/4/2014 11:18

me too ,

now 24% discount!

[tokyo sexwhale] 08/4/2014 10:57

Nav slightly up on yesterday agree way oversold now have added this morning

[philo124] 08/4/2014 09:49

Quite a discount; hold quite a lot of these plus BIOG and Tech IT's - most down 25% in a month so my strategy of these investments providing long term growth to sit along boring high income stocks is being put to the test.